Elmar Schnee was CEO of Cardiorentis in Zug, Switzerland from 2011–2013. Prior to this Elmar was the General Partner and member of the Executive Board of Merck KGaA, responsible for its worldwide pharmaceutical business in Rx and OTC with sales of € 6 Billion and 18’000 employees until June 2011. He also led the major restructuring of the business in acquiring Serono for € 10.3 billion and selling the Generic Division for € 4.9 billion. As CEO, he led the successful integration into Merck Serono until end of 2010. Prior to Merck, Elmar held senior roles in Marketing, Strategy and Business Development in UCB Brussels, Sanofi-Synthelabo in Paris, Migliara Kaplan in Baltimore and Fisons in UK.
Chief Executive Officer
David co-founded Moleac and has been serving as CEO since.
Prior to founding Moleac, David has spent ten years at the Boston Consulting Group (“BCG”) where he was a member of the worldwide Health Care Practice Area. He has worked both in Europe and in Asia. He has extensive experience in working in China and in Korea.
David graduated from the two top engineering schools in France, Ecole Polytechnique and Ecole Nationale Supérieure des Mines de Paris, where he majored in mathematics and economics. David also holds a French degree (“DESS”) in business law.
Xavier has gathered over 30 years of multi-category commercial experience holding general management tenure with a specific exposure in Life Science, Healthcare and biotech environment in several companies. Starting with Roquette Frères in 1985 then Pasteur Mérieux S&V, Aventis Pasteur MSD, Serono, Cegedim, Cider Santé, Arvem CS Europe and Cellectis bioresearch until 2014.
He worked in various countries in Asia, North and South America as well as Europe and has a successful track record in managing commercial organizations.
He founded Exicomes in 2014 and Thinkeen Europe in 2016 both consulting boutiques specifically dedicated to expanding commercial success in various technical and scientific environments.
Xavier holds a Master of Science in Biochemical Engineering and a DEA in Enzymology (1983) at University of Compiègne (France) and graduated a Master of Pharmaceutical Marketing at Ecole Supérieure de Commerce de Paris (1990) as well as the Advanced Management Program at INSEAD (2000).
Marc Cluzel M.D., Ph.D. got his degrees from the University of Montpellier, in France. He started as Assistant Professor at Montpellier Hospital then continued to become visiting Assistant Professor for 3 years at Johns Hopkins University before moving to Guy’s Hospital London as Research Associate in 1990. In 1991 he joined Sanofi as a clinical pharmacologist where he moved up to become Head of Sanofi R&D in January 2007. From 1996 to 2006 Marc chaired the development operational committee. He actively participated in the life management of Plavix, Aprovel and Taxotere and registration of Fasturtec, Eloxatin, Arixtra, Uro-Xatral, Ambien CR, Multaq and Jevtana, in the US. He initiated the research collaboration with Regeneron. In January 2011 he founded C&F consulting. He is the Chairman of Morphosys AG, being a board member of since May 2012. He is a board member at Griffon Pharmaceuticals Inc.. Marc advises Moleac on various issues, including R & D and Clinical Research.
Laurent is the Managing Partner of Hunza Ventures. In 2001 he originated and expanded this venture capital activity by developing investments in the biotech and medical device industries. Later on Laurent diversified Hunza Venture’s activities to the information technology industry. Since then Laurent has always contributed his entrepreneurial spirit and extensive management expertise to the success of Hunza Ventures’ portfolio companies.
In parallel, building on his extended experience in the real estate development market, Laurent created the Urbis group of companies of which Herpain-Urbis is the development arm that was set up as a JV with Herpain Investissement. On top of its real estate development activities, the Urbis group is also active in the private equity business through investments in companies operating mainly in the realm of the construction and real estate businesses.
Laurent is trained as a commercial engineer from the Solvay Business School and he is a Wharton School fellow.
Over his last 29 years at BCG, Philippe has advised several global companies in the Pharmaceutical, Biotech and Medical Device industries on a large range of topics such as Corporate and BU-Level Strategy, R&D, Commercial go-to-market and manufacturing as well as large-scale transformation and post-merger/acquisition integration.
Previously, Philippe has been the Global Leader of the BCG’s Healthcare Practice from 1997 to 2006. As a member of BCG’s Executive Committee, he was in charge of all BCG Practices from 2003 to 2006.
Philippe graduated from HEC (Hautes Etudes Commerciales).
Sean Low, CFA is the CEO and Chief Investment Officer of Golden Vision Capital (SIngapore) Pte Ltd, a single family office in Singapore. An industry veteran with 24 years of deal sourcing, investment and business development experience, (including 17 years in GIC PE & Infrastructure department), Sean is also senior advisor to Yangzijiang Financial Holdings Limited, an investment firm listed on SGX with NAV in excess S$4b. Sean started at Singapore Economic Development Board (EDB), first as Assistant Head of InfoComms & Media group, and then as Director of Chicago Centre. Sean currently chairs the Investment Committee at CFA Singapore, and was elected the Treasurer of Singapore’s VC & PE Association in 2021. He graduated from Trinity College, University of Cambridge with BA (1st Class Honours), MA and M Eng. (Honours).
Christophe Polini is the Company General Secretary of Tang Frères, where he has worked for more than a decade, first as legal director and since 2000 as its General Secretary. Christophe holds a Master in Laws and has worked in law firms and as the legal director of Afflelou.
Christophe brings to Moleac a strong experience of structuring and managing partnerships in China.
Gérard is a graduate of HEC Paris and attended the business management program of Stanford University (USA). He is a currently Member of the Strategic Board of Mérieux Equity Partners and a Board Member of several companies in the health care sector.
Prior to this, he founded and became CEO of Citicorp Venture Capital in Paris in 1984 and subsequently founded Schroder Ventures Paris (1989-1997). He has been responsible for four Venture and Buyout Funds. Gérard relocated to London in 1998 as a Director of Permira (formerly Schroder Ventures Europe). He founded the Sitka Health Fund VCT plc in 2000 which he sold to NFM in November 2005. He joined Mérieux Développement in 2009 as a member of the investment committee and regional Partner based in London. He has been nominated Conseiller du Commerce Extérieur in March 2007.
Sidney is advisor at Singapore’s Agency for Science, Technology and Research (A*STAR), Innovation & Enterprise division and founding CEO of Diagnostics Development (DxD) Hub, a national platform hosted by A*STAR. DxD Hub is a design, development and productisation hub for diagnostics solutions, with expertise and capability to rapidly translate R&D output from public and private sectors, into deployable medtech products. Sidney is founding co-chair of the ASEAN Diagnostics Development Initiative, as well as Adjunct Associate Professor at the Centre of Regulatory Excellence (CoRE), Duke-NUS Medical School, and Adjunct Associate Professor, NUS YLL School of Medicine (O&G) Sidney was lead of the Diagnostics Co-Operative of the Programme for Research in Epidemic Preparedness And Response (PREPARE), Singapore. PREPARE is Singapore’s national platform focusing on strengthening mid- to long-term R&D capabilities to prevent, prepare for and respond to future epidemics. Prior to joining A*STAR, Sidney co-founded and helped grow a number of startups in the biotech/medtech space. During her tenure at EDB Investments, Sidney led several investments in early stage companies in genomics, drug development and medical devices.
Co-Founder (†1949 -2013)
In 1989, Marc co-founded Genset and was been board member, Chief Biology Officer and General Manager of the company until 2000. Marc left Genset from July 2000 to March 2002. During this period, he was involved in the launch of a number of biotechnology companies spinning off from the Pasteur Institute. He came back to Genset in March 2002 and was appointed CEO and Chairman. He managed the acquisition of Genset by Serono through a tender offer. Marc then served as the CEO and Chairman of Serono France Holding. He created a new venture Sobios (Sophia Bio System) in France.
Marc also served as a Director of several other biotechnology companies and actively participated in advisory boards of several investment funds. Before launching Genset, Marc had been a director of biological research at L’Oreal, after working 10 years at the Pasteur Institute.
Marc was a former Professor of Virology at the University of Paris, and taught in many universities world-wide, including Zhongshan University in Guangzhou.
Marc co-founded Moleac and he contributed considerable experience and knowledge in research management, clinical and regulatory strategies Intellectual property management and business development.
Please wait while you are redirected to the right page...